"As the head of the R&D department, you actually said it's impossible? Why?"

Okada Murao looked at the subordinates in front of him, somewhat furious.

The director of the R&D department smiled bitterly and shook his head: "Mr. Okada, actually this is nothing new. Many pharmaceutical companies have thought about this, but unfortunately they have all failed."

"From Pfizer, Johnson & Johnson, to Takeda Pharmaceuticals, Daiichi Sankyo, etc., they have all tried to find new treatment directions from abandoned prescriptions, but none of them have succeeded."

"Such behavior is highly accidental and cannot be replicated. I believe that even if Sanqing succeeds, it is just bad luck. They will never be so lucky and succeed one after another."

As he explained, he cursed in his heart. The boss must have been under too much pressure recently, and his mind was confused. He had made assumptions and came up with such a bad idea of ​​using discarded prescriptions to develop new drugs.

How could he do something that even the global pharmaceutical giants cannot do?

If you force him to do it, won't it cost his life?

They also say that Sanqing can do it, why can't they do it?

This is not nonsense. Can anti-cancer drugs be developed by just anyone?

If they had this strength, they wouldn't have achieved nothing in ten years of research and development.

Importantly, discovering new treatment directions from abandoned pharmacies is not a great innovation.

In fact, all pharmaceutical companies and laboratories will conduct a variety of experiments when developing new drugs to confirm as many treatment directions as possible.

It is not uncommon for a new drug to suffer setbacks in its original R&D direction, then change its R&D direction and become revitalized.

When applying for marketing of innovative drugs, for the sake of safety, they will only apply for a treatment plan for one disease, and then carefully design experiments around this goal. Some will even select patients to obtain satisfactory experimental data, as far as possible.

Passed the review by FDA and other departments.

In this case, after the drug is put on the market, some new treatment directions are often discovered during treatment, which can be used for other unrelated diseases.

Even for many drugs that have been on the market for many years, after the patent expires, new treatment directions can be explored and patents for new diseases can be re-registered.

In this regard, the most classic case is the new use of an old drug, aspirin.

This best-selling drug has been used clinically for more than 100 years and has always been known for its significant antipyretic and analgesic effects.

But it has a serious side effect, which is that it can cause gastrointestinal bleeding and hemolytic anemia in patients.

In recent years, some teams have begun to study its effectiveness in anticoagulation and inhibiting platelet aggregation. They have used aspirin in patients with strokes and successfully discovered a series of new uses such as treating cerebral thrombosis and preventing myocardial infarction.

It can be said to be an example of an old tree blooming and the side effects counterattacking successfully.

Every pharmaceutical company dreams of exploring new research directions for its drugs before their patents expire.

But it’s not something you don’t want to think about, it’s something you can do.

The difficulty is not as easy as developing a brand new drug, and not every pharmaceutical company can realize their dream.

Luck is very important, but strength is even more important.

Only the top ten pharmaceutical companies in the industry have this strength. Not only can they continuously develop new drugs, but they can also develop new uses for new drugs.

R&D in new directions also requires a large investment in secondary clinical trials.

Therefore, pharmaceutical companies generally will not act rashly and will continue unless it is as obvious as Viagra.

Otherwise it will just be a waste of a lot of money for nothing.

Eisai Company's current capital scale cannot afford to waste so much money.

The R&D director is obviously not optimistic about the R&D strength of his department.

It is not easy to discover new treatment directions from successful new drugs, let alone find new treatment directions from abandoned prescriptions.

The difficulty of the two is not the same. The former can only be achieved by multinational giants, but the latter is simply a dream. Unless you are the chosen one who is extremely lucky, you will never be able to achieve it.

He didn't want to take on a task that was destined to fail, so he could only persuade his boss to give up this unrealistic idea.

Mr. Okamoto remained silent and his face turned ugly.

Under the well-founded persuasion of his subordinates, he finally regained some sanity.

As the R&D director said, it is indeed too difficult to discover new treatment directions from abandoned prescriptions.

He is not arrogant enough to think that he can easily accomplish things that top pharmaceutical companies cannot do.

If he had sufficient funds, he could certainly take the gamble, but he didn't.

But he quickly reacted, frowned, and thought about it.

Eisai doesn't have this ability, but Sanqing does.

Although he didn't know how the other party did it, his intuition made him think that the other party could definitely do it.

Otherwise, the other party’s confusing behavior of purchasing discarded prescriptions on a large scale cannot be explained.

If Wei Kang can't find new opportunities in discarded prescriptions, then why does it go on a purchasing spree?

In this case, why can't he seek cooperation with Sanqing by discarding the prescription?

It is said that the reason why Pfizer was able to reach an anti-cancer drug cooperation with Sanqing was because it provided the largest number of discarded prescriptions, and thus stood out from the many competitors in the bid.

"We don't have much cash left, probably about $100 million."

Okamoto pondered: "If this money is used to develop new drugs, it will definitely be a drop in the bucket and very difficult. But if it is used to purchase some discarded prescriptions, it will be relatively easy."

He made up his mind: "Hurry up and contact the pharmaceutical companies we have cooperated with and buy discarded prescriptions from them at high prices. I think they will not refuse such a good deal."

The R&D director was stunned: "Boss, you still refuse to give up. Do you still want to compete with Sanqing? This is not a good idea."

"The company's cash flow is already very tight, so we can't waste it all on this. Besides, Sanqing has more money than us now, so we can't compete with them."

Couldn’t even the bosses see the fate of those companies that had gone against Sanqing before?

Eisai is no longer what it used to be. Is a run-down pharmaceutical company with an annual revenue of only 2 billion going to fight Sanqing?

The pharmaceutical industry requires not only technology, but also sufficient funds. Those with insufficient funds cannot afford it.

The company needs money but no money, needs technology but no technology, and still wastes money on this kind of place.

If this continues, bankruptcy will happen sooner or later.

Thinking of this, he couldn't help but shudder, and several thoughts flashed through his mind.

Why don't you run away quickly and look for new opportunities?

Before it's too late, switch to a pharmaceutical company and find a new job?

I wonder if Sanqing has any plans to recruit people in Sakura Country. Since we can’t defeat them, why not join them?

His thoughts were racing here, but Mr. Okamoto smiled on the other side.

"Who said I would compete with Sanqing? I plan to use these prescriptions to cooperate with Wei Kang."

"Don't he want to abandon the prescription? Then I will collect more, and then use it to cooperate with him to develop new drug projects. Even if it only accounts for 10%, as long as the research and development is successful, it will be at least ten times the profit, or even

It’s a hundredfold profit, it’s a huge profit.”

"My method is very clever. As long as I have enough discarded prescriptions, I don't have to worry about Sanqing not cooperating with us. Hahaha~"

Mr. Okamoto's face turned red and he laughed triumphantly.

The R&D director was speechless. He wanted to remind his boss.

If it's so simple, why don't so many pharmaceutical companies do it?

He looked at the boss who was smiling so hard and his face was already a little distorted, and felt a chill in his heart, so he didn't dare to say anything again.

Instead, he lowered his head and responded loudly and respectfully.

"Hey, I got it, I'll do my best."

****

"Someone is buying up discarded prescriptions and raising the price?"

When Wei Kang learned the news from An Meina, he couldn't help but be surprised.

Besides him, there are also people who want to discard the prescription?

It's just a matter of acquiring discarded prescriptions. He has no control over it. Anyway, there are many pharmaceutical companies in the world, and there are always a lot of companies willing to sell.

But what's going on with this price increase? Is this to compete with him?

It’s not like no pharmaceutical company has done this before. They want to imitate Sanqing’s operation and recycle waste.

But after they bought it, they found that they could not develop any new treatment directions at all. They were just throwing money into the water without making a sound.

And if you want to stop Sanqing, you just need not to sell the prescriptions you have.

Just like Merck, since anti-cancer drugs were targeted and sales plummeted, they have never sold anything from Sanqing.

Purchasing discarded prescriptions from other pharmaceutical companies at such a high price can only harm oneself and benefit others, and give competitors a benefit, which is completely an act that outweighs the gains.

Which pharmaceutical company lost its mind and did such an outrageous thing?

He looked at the details and found that it was a relatively unknown pharmaceutical company.

"Eisai Pharmaceuticals of Sakura Country?"

"It used to be a pharmaceutical giant in the Sakura Country, but now its performance has declined significantly, and it can only stay in the domestic market."
To be continued...